AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|
18.1 C
New York
Thursday, October 29, 2026

Tag: period

newsFORsourcecompanycontentinformationreleases1market

Tariff Dodging Complaints Soar—Surprised?

US Customs and Border Protection (CBP) has seen a spike in reports of tariff dodging since Trump slapped new duties on over 100 countries....

EMA Confluence Validates Trend Continuation Setup

OverviewThe Multiple EMA Trend Confirmation Trading System is rooted in technical analysis, leveraging Exponential Moving Averages (EMAs) and multi-timeframe charts to identify trend direction...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

FinVolution Group Announces Proposed Offering of US$130 Million Convertible Senior Notes

SHANGHAI, June 19, 2025 /PRNewswire/ -- FinVolution Group ("FinVolution" or the "Company") (NYSE: FINV), a leading fintech platform in China, Indonesia and the Philippines,...

NORTHCLIFF ANNOUNCES NON-BROKERED PRIVATE PLACEMENT FINANCING

VANCOUVER, BC, June 19, 2025 /CNW/ - Northcliff Resources Ltd. ("Northcliff" or the "Company") (TSX: NCF) announces that it has arranged a non-brokered private...

ROSEN, LEADING INVESTOR COUNSEL, Encourages Fortrea Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FTRE

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”), of the important August 1, 2025 lead plaintiff deadline.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025.

HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight

The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other...

Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline |...

The delta-like ligand 3 targeted therapies market is witnessing significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine...

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Elevance Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELV

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DV

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline.

Investing Made Easy: Choose Your Core AI Stock – Nvidia or Palantir?

Hey there, fabulous women of finance! 🌟 Today, we're diving into the world of AI and exploring two tech-rockstar stocks: Nvidia and Palantir. These...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., June 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPeriod

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers